Next New Releases from NCBI BookshelfCiltacabtagene Autoleucel (Carvykti): Therapeutic area: Relapsed or refractory multiple myeloma: Reimbursement Review [Internet].Ciltacabtagene Autoleucel (Carvykti): Therapeutic area: Relapsed or refractory multiple myeloma: Reimbursement Review [Internet].